ArticleFrontiers in psychiatry2025
Association between GRIN2B DNA methylation and cognitive impairment: a cross-sectional study of patients with bipolar depression.
Article in Frontiers in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Tannic Acid Mitigates Monosodium Glutamate-Induced Cortical Damage by Modulating Synaptic and Calcium-Related Gene and Protein Expression.Journal of applied toxicology : JAT · 2026Article
- DNA methylation in bipolar disorder: mechanistic insights and translational challenges.Frontiers in pharmacology · 2026Review
- From synapse to system: mechanistic pathways of neural signaling dysfunction in psychiatric disorders.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cognitive impairment is a prevalent feature throughout the course of bipolar disorder (BD) and may contribute to recurrent episodes and poor prognosis. Despite its significant clinical impact, the biological mechanisms underlying cognitive impairment in BD remain poorly understood, complicating treatment efforts. The NR2B subunit of the N-methyl-D-aspartate (NMDA) receptor, encoded by the GRIN2B gene, plays a critical role in cognitive functions. Methods: In this study, we measured the methylation levels of the promoter region of the GRIN2B gene in peripheral blood samples from patients with bipolar depression and healthy controls using the MassARRAY method. Cognitive performance was assessed through a series of standardized neuropsychological tests. Subsequently, we analyzed the correlation between GRIN2B gene promoter methylation levels and cognitive performance in patients with bipolar depression. Results: We identified aberrant methylation levels at multiple CpG sites within the GRIN2B gene promoter region in patients with bipolar depression compared to healthy controls. These methylation changes were significantly associated with impairments in several cognitive domains, including attention and executive function, even after adjusting for potential confounding factors. These findings suggest that aberrant methylation in the GRIN2B gene promoter region may play a critical role in cognitive impairment in bipolar depression. Conclusions: DNA methylation levels in the GRIN2B gene promoter region may represent a potential therapeutic target for addressing cognitive impairment in bipolar depression. These findings provide a theoretical foundation for future clinical diagnosis and the development of targeted treatment strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.